Literature DB >> 23508114

Identifying transudates misclassified by Light's criteria.

José M Porcel1.   

Abstract

PURPOSE OF REVIEW: Light's criteria combine three dichotomous tests into a decision rule that is considered positive if any one of the tests is positive. This strategy clearly maximizes sensitivity, although at the expense of specificity. Although Light's criteria identify 98% of pleural exudates, they misclassify about 25% of transudates as exudates. The way to overcome this limitation is discussed in this review. RECENT
FINDINGS: Traditionally, measurement of the protein gradient between the serum and pleural fluid has been recommended to decrease the misclassification rate of Light's criteria. A recent study demonstrated that a gradient between the albumin levels in the serum and the pleural fluid more than 1.2 g/dl performs significantly better than a protein gradient more than 3.1 g/dl to correctly categorize mislabeled cardiac effusions (83 vs. 55%). On the other hand, the accuracy of a pleural fluid to serum albumin ratio less than 0.6 excelled when compared with albumin and protein gradients in patients with miscategorized hepatic hydrothoraces (77 vs. 62 vs. 61%).
SUMMARY: The simplest strategy to reveal the true transudative nature of heart failure-related effusions, labeled as exudates by Light's criteria, is to calculate the serum to pleural fluid albumin gradient. Conversely, for misclassified hepatic hydrothoraces, measurement of the pleural to serum albumin ratio is recommended. The serum to pleural fluid protein gradient should no longer be considered the preferred test for this purpose.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23508114     DOI: 10.1097/MCP.0b013e32836022dc

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  9 in total

1.  Significance of congestive heart failure as a cause of pleural effusion: Pilot data from a large multidisciplinary teaching hospital.

Authors:  Piotr Korczyński; Katarzyna Górska; Damian Konopka; Dżamila Al-Haj; Krzysztof J Filipiak; Rafał Krenke
Journal:  Cardiol J       Date:  2018-11-08       Impact factor: 2.737

Review 2.  Evaluation of the patient with pleural effusion.

Authors:  Stéphane Beaudoin; Anne V Gonzalez
Journal:  CMAJ       Date:  2018-03-12       Impact factor: 8.262

3.  Combination of Biochemical and Cytological Findings for Better Diagnosis in Pleural Effusions.

Authors:  Hatice Elmas; Christian Biancosino; Binnur Önal; Fernando Schmitt; Seyma Buyucek; Gerhard Nordholt; Guido Sauter; Lutz Welker
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

4.  Effectiveness and safety of diagnostic flexi-rigid thoracoscopy in differentiating exudative pleural effusion of unknown etiology: a retrospective study of 215 patients.

Authors:  Bao-An Gao; Gang Zhou; Li Guan; Ling-Yun Zhang; Guang-Ming Xiang
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

Review 5.  Malignant Pleural Effusion and Its Current Management: A Review.

Authors:  Kristijan Skok; Gaja Hladnik; Anja Grm; Anton Crnjac
Journal:  Medicina (Kaunas)       Date:  2019-08-15       Impact factor: 2.948

Review 6.  Can cholesterol be used to distinguish pleural exudates from transudates? evidence from a bivariate meta-analysis.

Authors:  Yongchun Shen; Hong Zhu; Chun Wan; Lei Chen; Tao Wang; Ting Yang; Fuqiang Wen
Journal:  BMC Pulm Med       Date:  2014-04-15       Impact factor: 3.317

7.  Diagnostic Value of Measurement Specific Gravity by Refractometric and Dipstick Method in Differentiation between Transudate and Exudate in Pleural and Peritoneal Fluid.

Authors:  Alireza Abdollahi; Zohreh Nozarian
Journal:  Iran J Pathol       Date:  2016

Review 8.  Hepatic hydrothorax: An update and review of the literature.

Authors:  Dmitry Victorovich Garbuzenko; Nikolay Olegovich Arefyev
Journal:  World J Hepatol       Date:  2017-11-08

Review 9.  Biomarkers in the diagnosis of pleural diseases: a 2018 update.

Authors:  José M Porcel
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.